Study of MK-2214 for early Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This trial tests an experimental medicine called MK-2214 for people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow memory and thinking problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have mild cognitive impairment or mild dementia caused by Alzheimer's disease.
- You need a study partner who can join visits and help answer questions about you.
- If you take approved Alzheimer's medications, your dose must have been stable for the last 3 months.
- You cannot have had a stroke, seizure, or other brain disease besides Alzheimer's.
- You cannot have a serious ongoing medical condition, liver disease, or unstable health issues.
- You must be willing to have brain scans (CT, PET, or MRI) and cannot live in a nursing home.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
This trial tests a new medicine called LY4006895 in two groups: healthy volunteers and people with early symptomatic Alzheimer's disease. It aims to see how the drug works in the body and if it might help memory and thinking.
This trial tests an investigational injection for people in the early stages of Alzheimer's. It aims to see if the drug can safely slow down memory loss and brain changes.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease. It aims to see if the drug is safe and can help slow memory decline.
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
Hear when a new Early Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.